Bundamedik Tbk PT
IDX:BMHS

Watchlist Manager
Bundamedik Tbk PT Logo
Bundamedik Tbk PT
IDX:BMHS
Watchlist
Price: 230 IDR -1.71% Market Closed
Market Cap: 2T IDR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+18%
Revenue
Forecast
+9%
Operating Income
Forecast
+9%
Net Income
Forecast
+9%

Wall Street
Price Targets

BMHS Price Targets Summary
Bundamedik Tbk PT

Wall Street analysts forecast BMHS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMHS is 295.8 IDR with a low forecast of 292.9 IDR and a high forecast of 304.5 IDR.

BMHS Lowest Forecast
Wall Street Target
292.9 IDR
27% Upside
BMHS Average Forecast
Wall Street Target
295.8 IDR
29% Upside
BMHS Highest Forecast
Wall Street Target
304.5 IDR
32% Upside
Lowest
Price Target
292.9 IDR
27% Upside
Average
Price Target
295.8 IDR
29% Upside
Highest
Price Target
304.5 IDR
32% Upside
Bundamedik Tbk PT Competitors:
Price Targets
EXE
Extendicare Inc
4% Upside
HCG
Healthcare Global Enterprises Ltd
1% Upside
P
PR9
Praram 9 Hospital PCL
25% Upside
A50
Thomson Medical Group Ltd
22% Upside
EXE
Extendicare Inc
4% Upside
HCG
Healthcare Global Enterprises Ltd
1% Upside
P
PR9
Praram 9 Hospital PCL
25% Upside
A50
Thomson Medical Group Ltd
22% Upside
R
RAM
Ramkhamhaeng Hospital PCL
75% Upside
A
300015
Aier Eye Hospital Group Co Ltd
17% Upside
M12
M1 Kliniken AG
74% Upside
R
RAINBOW
Rainbow Children's Medicare Ltd
17% Upside

Revenue
Forecast

Revenue Estimate
Bundamedik Tbk PT

For the last 5 years the compound annual growth rate for Bundamedik Tbk PT's revenue is 10%. The projected CAGR for the next 2 years is 13%.

10%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Bundamedik Tbk PT

For the last 5 years the compound annual growth rate for Bundamedik Tbk PT's operating income is -2%. The projected CAGR for the next 2 years is 40%.

-2%
Past Growth
40%
Estimated Growth
Estimates Accuracy
-20%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Bundamedik Tbk PT

For the last 5 years the compound annual growth rate for Bundamedik Tbk PT's net income is -10%. The projected CAGR for the next 2 years is 125%.

-10%
Past Growth
125%
Estimated Growth
Estimates Accuracy
-45%
Average Miss
What are analyst estimates?

See Also

Summary
BMHS intrinsic value, competitors valuation, and company profile.
DCF Valuation
BMHS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BMHS stock valuation using valuation multiples.
Wall Street Estimates
BMHS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BMHS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BMHS's stock price target?
Price Target
295.8 IDR

According to Wall Street analysts, the average 1-year price target for BMHS is 295.8 IDR with a low forecast of 292.9 IDR and a high forecast of 304.5 IDR.

What is Bundamedik Tbk PT's Revenue forecast?
Projected CAGR
13%

For the last 5 years the compound annual growth rate for Bundamedik Tbk PT's revenue is 10%. The projected CAGR for the next 2 years is 13%.

What is Bundamedik Tbk PT's Operating Income forecast?
Projected CAGR
40%

For the last 5 years the compound annual growth rate for Bundamedik Tbk PT's operating income is -2%. The projected CAGR for the next 2 years is 40%.

What is Bundamedik Tbk PT's Net Income forecast?
Projected CAGR
125%

For the last 5 years the compound annual growth rate for Bundamedik Tbk PT's net income is -10%. The projected CAGR for the next 2 years is 125%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 248,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.